0000939798-14-000115.txt : 20141216 0000939798-14-000115.hdr.sgml : 20141216 20141216103555 ACCESSION NUMBER: 0000939798-14-000115 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20141209 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141216 DATE AS OF CHANGE: 20141216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Growblox Sciences, Inc. CENTRAL INDEX KEY: 0001165320 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 593733133 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-82580 FILM NUMBER: 141288649 BUSINESS ADDRESS: STREET 1: 7251 W. LAKE MEAD BLVD. STREET 2: STE 300 CITY: LAS VEGAS STATE: NV ZIP: 89128 BUSINESS PHONE: (888) 895-3594 MAIL ADDRESS: STREET 1: 7251 W. LAKE MEAD BLVD. STREET 2: STE 300 CITY: LAS VEGAS STATE: NV ZIP: 89128 FORMER COMPANY: FORMER CONFORMED NAME: Signature Exploration & Production Corp. DATE OF NAME CHANGE: 20080602 FORMER COMPANY: FORMER CONFORMED NAME: Diabetic Treatment Centers of America, Inc. DATE OF NAME CHANGE: 20040812 FORMER COMPANY: FORMER CONFORMED NAME: FLAGSTICK VENTURES INC DATE OF NAME CHANGE: 20020117 8-K 1 gblxeightkregardingnewcfo.htm GBLX 8-K NEW CFO gblxeightkregardingnewcfo.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2014

Growblox Sciences, Inc.
(Exact name of Registrant as specified in its charter)


Delaware
(State or other Jurisdiction of
Incorporation or organization)
333-382580
(Commission File Number)
59-3733133
(IRS Employer I.D. No.)

7251 W. Lake Mead Blvd., Suite 300
Las Vegas, NV  89128
Phone: (844) 843-2569
Fax:  (866) 929-5122
(Address, including zip code, and telephone and facsimile numbers, including area code, of
registrant’s executive offices)

N/A
(Former name, former address and former fiscal year, if changed since last report)


 
- 1 -
 
ITEM 5.02 Resignation of Director and Officer; Appointment of Officer.
 
Effective December 9, 2014, Cathryn J. Kennedy joined the Registrant (hereinafter the “Company”) as its new Chief Financial Officer.
 
From 2013 to the present Ms. Kennedy served as controller and secretary to the board of directors of American Optical Services. American Optical Services owns and operates ophthalmology and optometry practices across the U.S.  As controller, she managed P&L, cash flow, implemented audit policies and managed financial reporting and tax return preparation with a national firm.  She managed a department of twenty five employees including personnel in the accounting and treasury departments.
 
From 2008 through 2013, Ms. Kennedy worked for eCommLink, Inc.  eCommLink, Inc. is a  prepaid card processor which supports a full array of global and domestic payments and transactions, which was sold via asset sale to Green Dot.  From 2011 to 2013 she served as CFO, from 2010 to 2011 she served as Vice President of Finance and as controller from 2008 to 2010.
 
From 2005 to 2008, Ms. Kennedy served as director of SEC reporting for Pinnacle Entertainment Inc., an entertainment company with 15 hotel and gaming operations located in the U.S.
 
Prior to 2005, she served as controller for American Wagering Inc. overseeing all corporate reporting, consolidations, financial preparations, preparation of SEC reports on forms 10QSB and 10KSB, and preparation of NGC tax filings, and oversaw gaming audits and compliance.
 
 
- 2 -
 
ITEM 9.01 Exhibits.
 
Attached as Exhibit 99 is a copy of the press release announcing the appointment of Cathryn J. Kennedy as the new CFO of the Company
 
SIGNATURE PAGE

Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Growblox Sciences, Inc.
  
         
Dated: December 16, 2014
  
By:
/s/ Craig Ellins
  
     
Craig Ellins
  
     
Chief Executive Officer and Chairman of the Board of Directors
  

 

 

 

 
- 3 -
 

EX-99 2 exhibitninetynint.htm PRESS RELEASE ANNOUNCING NEW CFO exhibitninetynint.htm
GrowBLOX Sciences Appoints Cathryn Kennedy as CFO

LAS VEGAS, DEC. 09, 2014 – GrowBLOX Sciences, Inc. (GBLX), a company that focuses on plant biology and cultivation technology in order to optimize safe and consistent medical cannabis, today announced the appointment of Cathryn Kennedy as its Chief Financial Officer, effective immediately.

“We are excited to have Ms. Kennedy join our team as Chief Financial Officer,” said GrowBLOX Sciences Inc. CEO Craig Ellins. “With experience in a number of different financial roles at firms ranging from start-ups to public companies, she will be invaluable in supporting our growth as we work to bring relief to patients in communities across the country through medical marijuana.”

Prior to joining GrowBLOX Sciences, Ms. Kennedy served in a number of financial roles, including as CFO of eCommLink Inc. and as Director of SEC Reporting at Pinnacle Entertainment Inc. between 2005 and 2008. She was integral in establishing corporate governance policies, managing complex transaction processing, and handling M&A in these previous roles.

“I am excited to join the team at GrowBLOX Sciences,” said Ms. Kennedy. “We are just starting to scratch the surface of  cannabis-based therapies potential to treat historically difficult diseases and conditions and I look forward to operating at the forefront of the industry alongside CEO Craig Ellins, CSO Andrea Small-Howard, and other members of the executive team to unlock this potential.”

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., "GB Sciences" (GBLX)—is a biopharmaceutical research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and big data-driven clinical research and development loop ability to bring relief to patients in communities across the country.

To learn more about GB Sciences, Inc., go to www.gbsciences.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Media and Investor Relations Contact:
Stephen Hart
Hayden IR
hart@haydenir.com
917-658-7878